Our Science
Pipeline
THERAPEUTICS
Drug
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
TriAx platform
ARB203
MOA:
Bispecific TCE
Indication:
GI cancers
ARB204
MOA:
Bispecific TCE
Indication:
Advanced GI cancers
ARB301
MOA:
Tri-specific TCE
Indication:
Advanced GI cancers
Antibody drug conjugate (ADC)
ARB101A
MOA:
Photosensitizer
Indication:
Advanced GI cancers
ARB102A
MOA:
Photo-caged Photosensitizer
Indication:
Advanced GI cancers
ARB103A
MOA:
FDA-approved drug
Indication:
Advanced GI cancers
Advanced Cell Therapy
ARB001
MOA:
CAR-T
Indication:
mCRC
ARB011
MOA:
CAR-NK/T
Indication:
Advanced GI cancers
Diagnostics
Platform
Intended Use
Prototyping /
Optimization
Manufacturing
Clinical Studies
Launch
CDH17 - IHC Test
GI cancer diagnostics
CDH17 - Blood Test
CRC screening /
surveillance
CDH17 - POCT
Point-of-CareTest
(Partnership with
Oxford Suzhou)
